Cerebral amyloid angiopathy increases susceptibility to infarction after focal cerebral ischemia in Tg2576 mice

Stroke

Volumn 45, Issue 10, 2014, Pages 3064-3069

  Milner, Eric ^a   Zhou, Meng Liang ^a   Johnson, Andrew W ^a   Vellimana, Ananth K ^a   Greenberg, Jacob K ^a   Holtzman, David M ^a   Han, Byung Hee ^a   Zipfel, Gregory J ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Alzheimer disease; amyloid angiopathy; amyloid peptide; brain ischemia; mice; transgenic

Indexed keywords

ACETYLCHOLINE; AMYLOID PRECURSOR PROTEIN;

AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL REACTIVITY; BRAIN BLOOD FLOW; BRAIN BLOOD VESSEL; BRAIN INFARCTION; BRAIN INFARCTION SIZE; BRAIN ISCHEMIA; CLINICAL ASSESSMENT; CONTROLLED STUDY; DISEASE PREDISPOSITION; DISEASE SEVERITY; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; MOUSE; NEUROLOGIC DISEASE; NONHUMAN; PRIORITY JOURNAL; SENILE PLAQUE; TG2576 MOUSE; VASCULAR AMYLOIDOSIS; WILD TYPE; ANIMAL; BRAIN; CEREBRAL INFARCTION; COMPLICATION; PATHOLOGY; PATHOPHYSIOLOGY; TRANSGENIC MOUSE; VASCULARIZATION;

ANIMALS; BRAIN; BRAIN ISCHEMIA; CEREBRAL AMYLOID ANGIOPATHY; CEREBRAL INFARCTION; DISEASE SUSCEPTIBILITY; MALE; MICE; MICE, TRANSGENIC;

EID: 84930166765     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.114.006078     Document Type: Article

References (43)

1. Iadecola C, Gorelick PB. Converging pathogenic mechanisms in vascular and neurodegenerative dementia. Stroke. 2003;34:335-337.
2. Iadecola C. Neurovascular regulation in the normal brain and in Alzheimer's disease. Nat Rev Neurosci. 2004;5:347-360.
3. Gorelick PB, Scuteri A, Black SE, Decarli C, Greenberg SM, Iadecola C, et al; American Heart Association Stroke Council, Council on Epidemiology and Prevention, Council on Cardiovascular Nursing, Council on Cardiovascular Radiology and Intervention, and Council on Cardiovascular Surgery and Anesthesia. Vascular contributions to cognitive impairment and dementia: A statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2011;42:2672-2713.
4. Vickrey BG, Brott TG, Koroshetz WJ; Stroke Research Priorities Meeting Steering Committee and the National Advisory Neurological Disorders and Stroke Council; National Institute of Neurological Disorders and Stroke. Research priority setting: A summary of the 2012 NINDS Stroke Planning Meeting Report. Stroke. 2013;44:2338-2342.
5. Hachinski VC, Lassen NA, Marshall J. Multi-infarct dementia. A cause of mental deterioration in the elderly. Lancet. 1974;2:207-210.
6. Jellinger KA. Alzheimer disease and cerebrovascular pathology: An update. J Neural Transm. 2002;109:813-836.
7. Mandybur TI. The incidence of cerebral amyloid angiopathy in Alzheimer's disease. Neurology. 1975;25:120-126.
8. Jellinger KA. The pathology of ischemic-vascular dementia: An update. J Neurol Sci. 2002;203-204:153-157.
9. Han BH, Zhou ML, Abousaleh F, Brendza RP, Dietrich HH, Koenigsknecht-Talboo J, et al. Cerebrovascular dysfunction in amyloid precursor protein transgenic mice: contribution of soluble and insoluble amyloid-beta peptide, partial restoration via gamma-secretase inhibition. J Neurosci. 2008;28:13542-13550.
10. Christie R, Yamada M, Moskowitz M, Hyman B. Structural and functional disruption of vascular smooth muscle cells in a transgenic mouse model of amyloid angiopathy. Am J Pathol. 2001;158:1065-1071.
11. Park L, Zhou P, Pitstick R, Capone C, Anrather J, Norris EH, et al. Nox2-derived radicals contribute to neurovascular and behavioral dysfunction in mice overexpressing the amyloid precursor protein. Proc Natl Acad Sci USA. 2008;105:1347-1352.
12. Tong XK, Nicolakakis N, Kocharyan A, Hamel E. Vascular remodeling versus amyloid beta-induced oxidative stress in the cerebrovascular dysfunctions associated with Alzheimer's disease. J Neurosci. 2005;25:11165-11174.
13. Paris D, Humphrey J, Quadros A, Patel N, Crescentini R, Crawford F, et al. Vasoactive effects of A beta in isolated human cerebrovessels and in a transgenic mouse model of Alzheimer's disease: role of inflammation. Neurol Res. 2003;25:642-651.
14. Smith EE, Vijayappa M, Lima F, Delgado P, Wendell L, Rosand J, et al. Impaired visual evoked flow velocity response in cerebral amyloid angiopathy. Neurology. 2008;71:1424-1430.
15. Dumas A, Dierksen GA, Gurol ME, Halpin A, Martinez-Ramirez S, Schwab K, et al. Functional magnetic resonance imaging detection of vascular reactivity in cerebral amyloid angiopathy. Ann Neurol. 2012;72:76-81.
16. Okazaki H, Reagan TJ, Campbell RJ. Clinicopathologic studies of primary cerebral amyloid angiopathy. Mayo Clin Proc. 1979;54:22-31.
17. Jellinger KA, Attems J. Prevalence and pathogenic role of cerebrovascular lesions in Alzheimer disease. J Neurol Sci. 2005;229-230:37-41.
18. Greenberg SM, Vonsattel JP, Stakes JW, Gruber M, Finklestein SP. The clinical spectrum of cerebral amyloid angiopathy: presentations without lobar hemorrhage. Neurology. 1993;43:2073-2079.
19. Neuropathology Group. Medical Research Council Cognitive function and Aging Study. Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales. Neuropathology Group of the Medical Research Council Cognitive Function and Ageing Study (MRC CFAS). Lancet. 2001;357:169-175.
20. Pfeifer LA, White LR, Ross GW, Petrovitch H, Launer LJ. Cerebral amyloid angiopathy and cognitive function: The HAAS autopsy study. Neurology. 2002;58:1629-1634.
21. Jellinger KA, Attems J. Prevalence and impact of cerebrovascular pathology in Alzheimer's disease and parkinsonism. Acta Neurol Scand. 2006;114:38-46.
22. Zhang F, Eckman C, Younkin S, Hsiao KK, Iadecola C. Increased susceptibility to ischemic brain damage in transgenic mice overexpressing the amyloid precursor protein. J Neurosci. 1997;17:7655-7661.
23. Koistinaho M, Kettunen MI, Goldsteins G, Keinänen R, Salminen A, Ort M, et al. Beta-amyloid precursor protein transgenic mice that harbor diffuse A beta deposits but do not form plaques show increased ischemic vulnerability: role of inflammation. Proc Natl Acad Sci USA. 2002;99:1610-1615.
24. Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, et al. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science. 1996;274:99-102.
25. Lee JM, Zipfel GJ, Park KH, He YY, Hsu CY, Choi DW. Zinc translocation accelerates infarction after mild transient focal ischemia. Neuroscience. 2002;115:871-878.
26. Milner E, Holtzman JC, Friess S, Hartman RE, Brody DL, Han BH, et al. Endovascular perforation subarachnoid hemorrhage fails to cause Morris water maze deficits in the mouse [published online ahead of print June 18, 2014]. J Cereb Blood Flow Metab. doi: http://dx. doi. org/10. 1038/ jcbfm. 2014. 108. Accessed July 7, 2014.
27. Han BH, Zhou ML, Vellimana AK, Milner E, Kim DH, Greenberg JK, et al. Resorufin analogs preferentially bind cerebrovascular amyloid: potential use as imaging ligands for cerebral amyloid angiopathy. Mol Neurodegener. 2011;6:86.
28. Dietrich HH, Xiang C, Han BH, Zipfel GJ, Holtzman DM. Soluble amyloid-beta, effect on cerebral arteriolar regulation and vascular cells. Mol Neurodegener. 2010;5:15.
29. Van Nostrand WE, Melchor J, Wagner M, Davis J. Cerebrovascular smooth muscle cell surface fibrillar A beta. Alteration of the proteolytic environment in the cerebral vessel wall. Ann N Y Acad Sci. 2000;903:89-96.
30. Shin HK, Jones PB, Garcia-Alloza M, Borrelli L, Greenberg SM, Bacskai BJ, et al. Age-dependent cerebrovascular dysfunction in a transgenic mouse model of cerebral amyloid angiopathy. Brain. 2007;130 (pt 9):2310-2319.
31. Van Nostrand WE, Melchor JP, Ruffini L. Pathologic amyloid betaprotein cell surface fibril assembly on cultured human cerebrovascular smooth muscle cells. J Neurochem. 1998;70:216-223.
32. Merlini M, Meyer EP, Ulmann-Schuler A, Nitsch RM. Vascular amyloid and early astrocyte alterations impair cerebrovascular function and cerebral metabolism in transgenic arcA mice. Acta Neuropathol. 2011;122:293-311.
33. Hawkes CA, Michalski D, Anders R, Nissel S, Grosche J, Bechmann I, et al. Stroke-induced opposite and age-dependent changes of vesselassociated markers in co-morbid transgenic mice with Alzheimer-like alterations. Exp Neurol. 2013;250:270-281.
34. Shankar GM, Leissring MA, Adame A, Sun X, Spooner E, Masliah E, et al. Biochemical and immunohistochemical analysis of an Alzheimer's disease mouse model reveals the presence of multiple cerebral Abeta assembly forms throughout life. Neurobiol Dis. 2009;36:293-302.
35. Kawarabayashi T, Younkin LH, Saido TC, Shoji M, Ashe KH, Younkin SG. Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer's disease. J Neurosci. 2001;21:372-381.
36. Johnson-Wood K, Lee M, Motter R, Hu K, Gordon G, Barbour R, et al. Amyloid precursor protein processing and A beta42 deposition in a transgenic mouse model of Alzheimer disease. Proc Natl Acad Sci USA. 1997;94:1550-1555.
37. Cirrito JR, May PC, O'Dell MA, Taylor JW, Parsadanian M, Cramer JW, et al. In vivo assessment of brain interstitial fluid with microdialysis reveals plaque-associated changes in amyloid-beta metabolism and halflife. J Neurosci. 2003;23:8844-8853.
38. McGowan E, Pickford F, Kim J, Onstead L, Eriksen J, Yu C, et al. Abeta42 is essential for parenchymal and vascular amyloid deposition in mice. Neuron. 2005;47:191-199.
39. Hong S, Quintero-Monzon O, Ostaszewski BL, Podlisny DR, Cavanaugh WT, Yang T, et al. Dynamic analysis of amyloid protein in behaving mice reveals opposing changes in ISF versus parenchymal A during age-related plaque formation. J Neurosci. 2011;31:15861-15869.
40. Maia LF, Kaeser SA, Reichwald J, Hruscha M, Martus P, Staufenbiel M, et al. Changes in amyloid and Tau in the cerebrospinal fluid of transgenic mice overexpressing amyloid precursor protein. Sci Transl Med. 2013;5:194re2.
41. Fagan AM, Mintun MA, Mach RH, Lee SY, Dence CS, Shah AR, et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol. 2006;59:512-519.
42. Verbeek MM, Kremer BP, Rikkert MO, Van Domburg PH, Skehan ME, Greenberg SM. Cerebrospinal fluid amyloid beta(40) is decreased in cerebral amyloid angiopathy. Ann Neurol. 2009;66:245-249.
43. Herzig MC, Winkler DT, Burgermeister P, Pfeifer M, Kohler E, Schmidt SD, et al. Abeta is targeted to the vasculature in a mouse model of hereditary cerebral hemorrhage with amyloidosis. Nat Neurosci. 2004;7:954-960.